Dr. Christopher King’s principal interest has been in prostate cancer. His research has concentrated mainly in the clinical, pathologic and biologic markers for tumor aggressiveness and response to radiotherapy. He has defined several clinical questions in the optimal treatment of prostate cancer, both in the primary setting and in the post-operative setting, that have been the basis of several clinical trials. He is currently the principal investigator of an ongoing clinical trial treating localized prostate cancer using a specialized technique called stereotactic body radiotherapy.
Selected Cancer-Related Publications:
King CR, Kapp DS. To treat pelvic nodes or not: could the greater testicular scatter dose from whole pelvic fields confound results of prostate cancer trials? J Clin Oncol. 2009 Dec 20;27(36):6076-8. Epub 2009 Oct 26.
King CR, Spiotto MT. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):23-7. Epub 2008 Jan 22.
King CR, Ferrari M, Brooks JD. Prognostic significance of prostate cancer originating from the transition zone. Urol Oncol. 2009 Nov-Dec;27(6):592-7. Epub 2008 Sep 16.
King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC Jr. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1043-8. Epub 2008 Aug 26.
Patel DA, Presti JC Jr, McNeal JE, Gill H, Brooks JD, King CR. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol. 2005 Sep 1;23(25):6157-62.